# Diamond Therapeutics

**Location:** Toronto, Canada

**Focus:** Psilocybin-assisted therapy for anxiety disorders

**Stage:** Phase 2a clinical trials

## Clinical Programs

**Generalized Anxiety Disorder (GAD):**
- Phase 2a psilocybin trial data being contributed to ARPA-H EVIDENT initiative
- GAD represents largest single anxiety disorder population (~40M US sufferers)
- Larger addressable market than treatment-resistant depression (TRD) or PTSD

## Strategic Position

Diamond Therapeutics is notable as a Canadian company selected for US government-funded research infrastructure (ARPA-H EVIDENT), demonstrating international data integration into US regulatory pathways. The GAD indication differentiates from most psychedelic research focused on depression or PTSD.

## Timeline

- **2026-04-24** — Selected as ARPA-H EVIDENT research team, contributing Phase 2a psilocybin GAD trial data

## Analysis

The GAD indication is strategically significant: if psilocybin demonstrates efficacy for generalized anxiety disorder, the addressable population exceeds TRD and PTSD combined. GAD affects ~6.8M US adults annually (3.1% of population), with lifetime prevalence near 9%. Current first-line treatments (SSRIs, SNRIs, benzodiazepines) have limited efficacy and significant side effect profiles, creating unmet medical need.

Diamond's inclusion in ARPA-H EVIDENT despite being a non-US company indicates that psychedelic research infrastructure is genuinely international, with US regulatory agencies willing to incorporate foreign clinical data into domestic approval pathways.